By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SDIX today reported that its fourth-quarter revenues dipped 13 percent year over year, as its Life Science business dropped 11 percent.

For the period ended Dec. 31, 2011, total revenues were $5.5 million, down from $6.3 million a year ago. Life Science brought in revenues of $3.8 million, compared to $4.2 million in Q4 2010, a drop that the company attributed to order timing in the IVD business as larger orders were placed earlier during 2011.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.